These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 17264301

  • 1. How I treat patients with polycythemia vera.
    Finazzi G, Barbui T.
    Blood; 2007 Jun 15; 109(12):5104-11. PubMed ID: 17264301
    [Abstract] [Full Text] [Related]

  • 2. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
    Finazzi G.
    Semin Thromb Hemost; 2006 Apr 15; 32(3):276-82. PubMed ID: 16673282
    [Abstract] [Full Text] [Related]

  • 3. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep 15; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

  • 4. The treatment of polycythaemia vera: an update in the JAK2 era.
    Finazzi G, Barbui T.
    Intern Emerg Med; 2007 Mar 15; 2(1):13-8. PubMed ID: 17551678
    [Abstract] [Full Text] [Related]

  • 5. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Cancer J; 2007 Mar 15; 13(6):372-6. PubMed ID: 18032974
    [Abstract] [Full Text] [Related]

  • 6. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun 15; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 7. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2019 Jan 15; 94(1):133-143. PubMed ID: 30281843
    [Abstract] [Full Text] [Related]

  • 8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 15; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 9. Diagnosis and therapy of polycythemia vera.
    Lengfelder E, Merx K, Hehlmann R.
    Semin Thromb Hemost; 2006 Apr 15; 32(3):267-75. PubMed ID: 16673281
    [Abstract] [Full Text] [Related]

  • 10. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar 15; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 11. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G, Barbui T.
    Leukemia; 2008 Aug 15; 22(8):1494-502. PubMed ID: 18596737
    [Abstract] [Full Text] [Related]

  • 12. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2013 Jun 15; 88(6):507-16. PubMed ID: 23695894
    [Abstract] [Full Text] [Related]

  • 13. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L, Newberry KJ, Verstovsek S.
    Clin Lymphoma Myeloma Leuk; 2015 Jun 15; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [Abstract] [Full Text] [Related]

  • 14. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2011 Mar 15; 86(3):292-301. PubMed ID: 21351120
    [Abstract] [Full Text] [Related]

  • 15. [Recent advances in polycythemia vera treatment].
    Edahiro Y.
    Rinsho Ketsueki; 2020 Mar 15; 61(9):1187-1194. PubMed ID: 33162515
    [Abstract] [Full Text] [Related]

  • 16. Thromboembolic events in polycythemia vera.
    Griesshammer M, Kiladjian JJ, Besses C.
    Ann Hematol; 2019 May 15; 98(5):1071-1082. PubMed ID: 30848334
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA.
    Semin Oncol; 2002 Jun 15; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [Abstract] [Full Text] [Related]

  • 18. Risk factors and prevention of vascular complications in polycythemia vera.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 1997 Jun 15; 23(5):455-61. PubMed ID: 9387204
    [Abstract] [Full Text] [Related]

  • 19. Evidence-based management of polycythemia vera.
    Barbui T, Finazzi G.
    Best Pract Res Clin Haematol; 2006 Jun 15; 19(3):483-93. PubMed ID: 16781485
    [Abstract] [Full Text] [Related]

  • 20. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T, Finazzi MC, Finazzi G.
    Blood Rev; 2012 Sep 15; 26(5):205-11. PubMed ID: 22784966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.